Risankizumab

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi benefitted from an additional 12 weeks of treatment, according to study results in Clinical Gastroenterology and Hepatology.

PHILADELPHIA — Risankizumab outperformed placebo in endoscopic improvement and remission through 52 weeks of maintenance therapy in moderately to severely active ulcerative colitis, regardless of induction outcomes, according to data.

Ethan Craig, MD, spoke with Healio about treatment options currently available in psoriatic arthritis.

Risankizumab showed a significant improvement in psoriasis severity and quality of life in biologic-naïve patients and in those previously treated with other biologics, according to a study.

Early endoscopic improvement after Skyrizi induction was associated with fewer Crohn’s disease-related hospitalizations and surgeries through 52 weeks of maintenance in patients with moderately to severely active disease, research showed.

Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in patients with moderate to severe Crohn’s disease, according to data from the SEQUENCE trial.

Skyrizi significantly improved clinical remission rates as both induction and maintenance therapy vs. placebo in patients with moderately to severely active ulcerative colitis, according to data from the phase 3 INSPIRE and COMMAND trials.

The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.

In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, discusses new study results assessing the use of interleukin-23 inhibitors in ulcerative colitis.

WASHINGTON — A maintenance dose of subcutaneous Skyrizi may still induce clinical response in patients with ulcerative colitis who failed to achieve response after 12 weeks of IV induction, noted a presenter at Digestive Disease Week.